Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nintedanib Esylate

FDA-approved product (capsule, oral), marketed as Nintedanib Esylate, Ofev.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nintedanib Esylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic pulmonary fibrosis
  • Interstitial pneumonitis
  • Non-small cell lung carcinoma
  • Systemic scleroderma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nintedanib Esylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nintedanib Esylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

    NCT02551068 · start 2015-12

    Registered record
    Registry ID
    NCT02551068
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    60% Oxygen; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-12
    Completion
    2025-08
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    Intervention60% Oxygen; Standard of Care
    PhaseNot applicable
    Registry statusCompleted

  • A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

    NCT02597933 · start 2015-11-12

    Registered record
    Registry ID
    NCT02597933
    Conditions
    Scleroderma, Systemic
    Interventions
    Nintedanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-12
    Completion
    2018-11-28
    Enrolment
    580

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScleroderma, Systemic
    InterventionNintedanib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

    NCT02389764 · start 2015-06-22

    Registered record
    Registry ID
    NCT02389764
    Conditions
    Breast Cancer
    Interventions
    BIBF 1120; Phone Call
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-06-22
    Completion
    2019-06-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionBIBF 1120; Phone Call
    PhasePhase 2
    Registry statusTerminated

  • Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

    NCT02225405 · start 2015-04-03

    Registered record
    Registry ID
    NCT02225405
    Conditions
    Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions
    Cisplatin; Docetaxel; Laboratory Biomarker Analysis; Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04-03
    Completion
    2024-05-06
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 +1 more
    InterventionCisplatin; Docetaxel; Laboratory Biomarker Analysis; Nintedanib
    PhasePhase 1
    Registry statusCompleted

  • Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

    NCT02866370 · start 2015-04

    Registered record
    Registry ID
    NCT02866370
    Conditions
    Ovarian Clear Cell Carcinoma; Endometrial Clear Cell Carcinoma
    Interventions
    Nintedanib; Paclitaxel; Pegylated Liposomal Doxorubicin (PLD); Topotecan; Carboplatin; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2021-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Clear Cell Carcinoma; Endometrial Clear Cell Carcinoma
    InterventionNintedanib; Paclitaxel; Pegylated Liposomal Doxorubicin (PLD); Topotecan +2 more
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

    NCT02308553 · start 2015-03-17

    Registered record
    Registry ID
    NCT02308553
    Conditions
    Cutaneous Malignant Melanoma
    Interventions
    Nintedanib; Nintedanib-Placebo; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03-17
    Completion
    2019-11
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Malignant Melanoma
    InterventionNintedanib; Nintedanib-Placebo; Paclitaxel
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)

    NCT01684111 · start 2013-06

    Registered record
    Registry ID
    NCT01684111
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    BIBF 1120; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    Not recorded
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionBIBF 1120; Vinorelbine
    PhasePhase 1
    Registry statusCompleted

  • BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

    NCT01669798 · start 2013-02

    Registered record
    Registry ID
    NCT01669798
    Conditions
    Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2018-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
    InterventionBIBF 1120
    PhasePhase 2
    Registry statusCompleted

  • BIBF 1120 for Recurrent High-Grade Gliomas

    NCT01380782 · start 2012-05

    Registered record
    Registry ID
    NCT01380782
    Conditions
    Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-07
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma +1 more
    InterventionBIBF 1120
    PhasePhase 2
    Registry statusCompleted

  • Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

    NCT01485874 · start 2011-11

    Registered record
    Registry ID
    NCT01485874
    Conditions
    Ovarian Cancer
    Interventions
    Doxil (Pegylated Liposomal Doxorubicin); BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2015-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionDoxil (Pegylated Liposomal Doxorubicin); BIBF 1120
    PhasePhase 1
    Registry statusTerminated

  • TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)

    NCT01362361 · start 2011-06

    Registered record
    Registry ID
    NCT01362361
    Conditions
    Colorectal Cancer
    Interventions
    mFOLFOX6 + BIBF 1120; mFOLFOX6+placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-06
    Completion
    2016-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionmFOLFOX6 + BIBF 1120; mFOLFOX6+placebo
    PhasePhase 2
    Registry statusCompleted

  • Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

    NCT01329549 · start 2011-04

    Registered record
    Registry ID
    NCT01329549
    Conditions
    Ovarian Neoplasms
    Interventions
    BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-04
    Completion
    2012-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms
    InterventionBIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
    PhasePhase 1
    Registry statusTerminated

  • Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

    NCT01170065 · start 2010-06-25

    Registered record
    Registry ID
    NCT01170065
    Conditions
    Pulmonary Fibrosis
    Interventions
    BIBF 1120; BIBF 1120; BIBF 1120; BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06-25
    Completion
    2016-09-26
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Fibrosis
    InterventionBIBF 1120; BIBF 1120; BIBF 1120; BIBF 1120
    PhasePhase 2
    Registry statusCompleted

  • A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

    NCT00987935 · start 2009-10

    Registered record
    Registry ID
    NCT00987935
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Sorafenib; BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2016-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionSorafenib; BIBF 1120
    PhasePhase 2
    Registry statusCompleted

  • A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

    NCT02182128 · start 2006-06

    Registered record
    Registry ID
    NCT02182128
    Conditions
    Tumors
    Interventions
    BIBF 1120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors
    InterventionBIBF 1120
    PhasePhase 1
    Registry statusCompleted